A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). METHOD: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day. Repetitive behaviors were measured with the compulsion subscale of the Yale-Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. RESULTS: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. CONCLUSIONS: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A few studies have also focused on the hypothesis that, at the level of neural circuits, ASD may result from excessive excitation or insufficient inhibition 213 , with some promising but inconclusive results for medicines that target the GABAergic system 214 .”
From Autism spectrum disorder (2020) · cites this paper as [213]
In the citing paper
“increased rates of behavioral activation, impulsiveness, and stereotypy have been observed in studies examining the use of SSRIs among patients with ASD for the treatment of restricted and repetitive behaviors [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
In the citing paper
“Some trials of SSRIs evaluated depression as a secondary outcome measure, but they did not recruit for clinically significant depression in their participant cohort [118].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [118]
Citations
Cites
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Leventhal, B. L., DiLavore, P. C., Pickles, A., & Rutter, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005592401947 · Cited by 7,520
Adult outcome for children with autism
Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2004.00215.x · Cited by 1,813
Autism From 2 to 9 Years of Age
Lord, C., Risi, S., DiLavore, P. S., Shulman, C., Thurm, A., & Pickles, A. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.694 · Cited by 973
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle, C. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110037005 · Cited by 556
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationA Five to Fifteen Year Follow-Up Study of Infantile Psychosis: II. Social and Behavioural Outcome
Rutter, M., Greenfeld, D., & Lockyer, L. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1183 · Cited by 476
Research works printed but not linked: 2
- 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9 · doi:10.1002/1531-8249(199903)45:3<287::aid-ana3>3.0.co;2-9
- Aman MG, 1985, Am J Ment Defic, 89, 485
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)
Genovese, A., & Butler, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134726 · Cited by 268
“Fluoxetine has been shown to improve repetitive behaviours in adults with ASD [97]; however, benefit has not been reliably demonstrated in pediatric populations.”
BackgroundAn update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
An update on pharmacotherapy of autism spectrum disorder in children and adolescents
Goel, R., Hong, J. S., Findling, R. L., & Ji, N. Y. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1458706 · Cited by 176
“In contrast, Autism Speaks released findings from an unpublished industry-sponsored large RDBPC study of fluoxetine in children and adolescents with ASD (SOFIA), indicating no improvement in RRB (Autism Speaks Press release, 2009).”
BackgroundInfluentialObesity in Children with Autism Spectrum Disorder
Curtin, C., Jojic, M., & Bandini, L. G. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000031 · Cited by 175
Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics
Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_5003 · Cited by 170
Autism spectrum disorders: an overview on diagnosis and treatment
Brentani, H., Paula, C. S. D., Bordini, D., Rolim, D., Sato, F., Portolese, J., Pacifico, M. C., & McCracken, J. T. (2013) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2013-s104 · Cited by 166
Pharmacological therapies for autism spectrum disorder: a review.
(2015) · PubMed Central · Cited by 150
Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder
Dhaliwal, K. K., Orsso, C. E., Richard, C., Haqq, A. M., & Zwaigenbaum, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133285 · Cited by 140
“Previous research on the efficacy of citalopram [119] and fluoxetine [120] in children with ASD have not examined changes in weight gain.”
BackgroundDoyle, C. A., & McDougle, C. J. (2012) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2012.14.3/cdoyle · Cited by 136
Siafis, S., Çıray, O., Wu, H., Schneider-Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., et al. (2022) · Molecular Autism · doi:10.1186/s13229-022-00488-4 · Cited by 126
“In adults, however, fluoxetine and fluvoxamine improved repetitive behaviors with large effect-sizes, yet based on single small (n = 30–37) studies [65, 66].”
BackgroundAnxiety Disorders in Adults with Autism Spectrum Disorder: A Population-Based Study
Nimmo-Smith, V., Heuvelman, H., Dalman, C., Lundberg, M., Idring, S., Carpenter, P., Magnusson, C., & Rai, D. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04234-3 · Cited by 128
Psychopharmacological interventions in autism spectrum disorder
Accordino, R. E., Kidd, C., Politte, L. C., Henry, C. A., & McDougle, C. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154536 · Cited by 126
Zhou, M. S., Nasir, M., Farhat, L. C., Kook, M., Artukoglu, B. B., & Bloch, M. H. (2021) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.03.007 · Cited by 121
Compulsivity, impulsivity, and the DSM-5 process
Berlin, G. S., & Hollander, E. (2014) · CNS Spectrums · doi:10.1017/s1092852913000722 · Cited by 120
Self-citationDrd3 Signaling in the Lateral Septum Mediates Early Life Stress-Induced Social Dysfunction
Shin, S., Pribiag, H., Lilascharoen, V., Knowland, D., Wang, X.-Y., & Lim, B. K. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.040 · Cited by 120
Medications for Adolescents and Young Adults With Autism Spectrum Disorders: A Systematic Review
Dove, D., Warren, Z., McPheeters, M. L., Taylor, J. L., Sathe, N. A., & Veenstra-VanderWeele, J. (2012) · Pediatrics · doi:10.1542/peds.2012-0683 · Cited by 115
Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research
Farmer, C., Thurm, A., & Grant, P. (2013) · Drugs · doi:10.1007/s40265-013-0021-7 · Cited by 115
Obsessive-Compulsive Disorder and Autism Spectrum Disorders: Longitudinal and Offspring Risk
Meier, S. M., Petersen, L., Schendel, D. E., Mattheisen, M., Mortensen, P. B., & Mors, O. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141703 · Cited by 114
Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study
Sharma, A., Gokulchandran, N., Sane, H., Nagrajan, A., Paranjape, A., Kulkarni, P., Shetty, A., Mishra, P., Kali, M., Biju, H., et al. (2013) · Stem Cells International · doi:10.1155/2013/623875 · Cited by 110
“The exclusion criteria were presence of acute infections such as HIV/HBV/HCV, malignancies, bleeding tendencies, renal failure, severe liver dysfunction and other acute medical conditions such as respiratory infection and pyrexia.”
MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults
Danforth, A. L., Struble, C. M., Yazar-Klosinski, B., & Grob, C. S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.011 · Cited by 110
“For example, off-label prescription of SSRIs is on the rise in this population (Hollander et al., 2012).”
BackgroundReddihough, D. S., Marraffa, C., Mouti, A., O’Sullivan, M., Lee, K. J., Orsini, F., Hazell, P., Granich, J., Whitehouse, A. J. O., Wray, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.14685 · Cited by 99
Zürcher, N. R., Bhanot, A., McDougle, C. J., & Hooker, J. M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.02.002 · Cited by 111
Association of rigid-compulsive behavior with functional constipation in autism spectrum disorder
Marler, S., Ferguson, B. J., Lee, E. B., Peters, B., Williams, K. C., McDonnell, E., Macklin, E. A., Levitt, P., Margolis, K. G., Beversdorf, D. Q., et al. (2017) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-017-3084-6 · Cited by 94
Aliko, A., Wolff, Ä., Dawes, C., Aframian, D. J., Proctor, G., Ekström, J., Narayana, N., Villa, A., Sia, Y. W., Joshi, R. K., et al. (2015) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2014.10.027 · Cited by 114
Harrington, R. A., Lee, L., Crum, R. M., Zimmerman, A. W., & Hertz‐Picciotto, I. (2013) · Autism Research · doi:10.1002/aur.1288 · Cited by 92
Severity of Autism Spectrum Disorders: Current Conceptualization, and Transition to DSM-5
Mehling, M. H., & Tassé, M. J. (2016) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-016-2731-7 · Cited by 89
Dougherty, J. D., Maloney, S. E., Wozniak, D. F., Rieger, M. A., Sonnenblick, L., Coppola, G., Mahieu, N. G., Zhang, J., Cai, J., Patti, G. J., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4762-12.2013 · Cited by 89
Hsia, Y., Wong, A. Y. S., Murphy, D., Simonoff, E. A., Buitelaar, J. K., & Wong, I. C. K. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3263-x · Cited by 101
Bipolar disorder in adults with Asperger׳s Syndrome: A systematic review
Vannucchi, G., Masi, G., Toni, C., Dell’Osso, L., Erfurth, A., & Perugi, G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.042 · Cited by 102
Immune Dysregulation in Autism Spectrum Disorder
Hsiao, E. Y. (2013) · International Review of Neurobiology · doi:10.1016/b978-0-12-418700-9.00009-5 · Cited by 87
Garbarino, V. R., Gilman, T. L., Daws, L. C., & Gould, G. G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.010 · Cited by 85
“For example, only a minority (approximately 35%) of children and adolescents [132] with ASD exhibit reduced irritability, stereotypies, and inappropriate speech and hyperactivity when receiving SSRI treatment [132–135].”
Template to Perpetrate: An Update on Violence in Autism Spectrum Disorder
Im, D. S. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000087 · Cited by 81
Amodeo, D. A., Jones, J. H., Sweeney, J. A., & Ragozzino, M. E. (2014) · Autism Research · doi:10.1002/aur.1395 · Cited by 79
CRISPR/Cas9-mediated disruption of SHANK3 in monkey leads to drug-treatable autism-like symptoms
Tu, Z., Zhao, H., Li, B., Yan, S., Wang, L., Tang, Y., Li, Z., Bai, D., Li, C., Lin, Y., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy367 · Cited by 81
Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion
Daly, E., Ecker, C., Hallahan, B., Deeley, Q., Craig, M., Murphy, C., Johnston, P., Spain, D., Gillan, N., Gudbrandsen, M., et al. (2014) · Brain · doi:10.1093/brain/awu178 · Cited by 73
Psychopharmacological Interventions in Autism Spectrum Disorder
Politte, L. C., Henry, C. A., & McDougle, C. J. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000030 · Cited by 71
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., LEVENTHAL, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-2477-9 · Cited by 79
“Clinical outcome Among the 14 RCT studies found eligible, six found significant improvement as assessed by RRBs scales when comparing medication and placebo groups: two on risperidone [31, 40]; one on fluvoxamine [30]; one on fluoxetine [39]; one on Buspirone [41] and, one divalproex sodium [33].”
BackgroundTargets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
Lacivita, E., Perrone, R., Margari, L., & Leopoldo, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00965 · Cited by 79
Herscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., Hendren, R., Kolevzon, A., Melmed, R., Mintz, M., et al. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04120-y · Cited by 62
Pharmacotherapy of autism spectrum disorders
Benvenuto, A., Battan, B., Porfirio, M. C., & Curatolo, P. (2012) · Brain and Development · doi:10.1016/j.braindev.2012.03.015 · Cited by 72
“Use of fluoxetine has brought an improvement in overall function and profound positive effects on irritability, stereotypy, and inappropriate speech in children and adults with ASDs [59,60].”
BackgroundChantiluke, K., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., Murphy, D. G., & Rubia, K. (2015) · Cerebral Cortex · doi:10.1093/cercor/bht365 · Cited by 59
Robson, M. J., Quinlan, M. A., Margolis, K. G., Gajewski-Kurdziel, P. A., Veenstra-VanderWeele, J. M., Gershon, M. D., Watterson, D. M., & Blakely, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809137115 · Cited by 62
“In contrast, some benefit has been reported for SSRIs in adults with ASD (84, 85).”
BackgroundZhang, W. Q., Smolik, C. M., Barba-Escobedo, P. A., Gamez, M., Sanchez, J. J., Javors, M. A., Daws, L. C., & Gould, G. G. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.024 · Cited by 56
Lamy, M., & Erickson, C. A. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2018.08.015 · Cited by 69
Brain hyperserotonemia causes autism-relevant social deficits in mice
Tanaka, M., Sato, A., Kasai, S., Hagino, Y., Kotajima‐Murakami, H., Kashii, H., Takamatsu, Y., Nishito, Y., Inagaki, M., Mizuguchi, M., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0243-3 · Cited by 66
Deb, S., Roy, M., Lee, R., Majid, M., Limbu, B., Santambrogio, J., Roy, A., & Bertelli, M. O. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1003 · Cited by 49
Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., et al. (2025) · BMC Medicine · doi:10.1186/s12916-024-03814-0 · Cited by 51
“Some trials of SSRIs evaluated depression as a secondary outcome measure, but they did not recruit for clinically significant depression in their participant cohort [118].”
The psychopharmacology of autism spectrum disorder and Rett syndrome
Persico, A. M., Ricciardello, A., & Cucinotta, F. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00024-1 · Cited by 61
An Update on Medication Management of Behavioral Disorders in Autism
Baribeau, D. A., & Anagnostou, E. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0437-0 · Cited by 62
Self-citationIffland, M., Livingstone, N., Jorgensen, M. L., Hazell, P., & Gillies, D. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011769.pub2 · Cited by 72
Nakai, N., Takumi, T., Nakai, J., & Sato, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00412 · Cited by 52
“Similarly, a double-blind placebo-controlled 12-week parallel study of 37 adults [1860 years old; 65% Asperger, 32% ASD and 3% pervasive developmental disorder not otherwise specified (PDD-NOS)] found a significantly greater reduction in repetitive behaviors in the fluoxetine-treated group (10-80 mg/d) than in the pla…”
BackgroundEvidence-Based Treatments for Autism Spectrum Disorder
Politte, L. C., Howe, Y. J., Nowinski, L. A., Palumbo, M., & McDougle, C. J. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0031-z · Cited by 57
Fusar‐Poli, L., Brondino, N., Rocchetti, M., Petrosino, B., Arillotta, D., Damiani, S., Provenzani, U., Petrosino, C., Aguglia, E., & Politi, P. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.04.013 · Cited by 49
三戸, 宏., Matsuura, N., Mukai, K., Yanagisawa, Y., Nakajima, A., Motoyama, M., Arikawa, A., Yamanishi, K., & Matsunaga, H. (2014) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2014.05.005 · Cited by 56
“Thus, even though it has yet to be confirmed whether SSRI effectively reduce ASD symptoms, especially repetitive behaviors, the predominance of higher-order repetitive behaviors rather than lower-order repetitive behaviors or hoarding may be associated with marked responses to SSRI in autistic adults [46].”
BackgroundUutela, M., Lindholm, J., Rantamäki, T., Umemori, J., Hunter, K., Võikar, V., & Castrén, M. L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00150 · Cited by 39
“…for core features of ASD in adults (Williams et al., 2013) and in individual cases and subgroups of children with autism (DeLong et al., 1998, 2002; Hollander et al., 2012), a recent meta-analysis indicates that there is not enough evidence to support the use of SSRIs in autism (Williams et al.,…”
BackgroundResultInfluentialBertelli, M. O., Azeem, M. W., Underwood, L., Scattoni, M. L., Persico, A. M., Ricciardello, A., Sappok, T., Bergmann, T. J., Keller, R., Bianco, A., et al. (2022) · Springer eBooks · doi:10.1007/978-3-319-95720-3_16 · Cited by 48
Lamy, M., Pedapati, E. V., Dominick, K. C., Wink, L. K., & Erickson, C. A. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00408-0 · Cited by 43
“Fluoxetine has demonstrated potential efficacy in reducing repetitive behaviors in a small-scale, double-blind, placebo-controlled trial in adults with ASD [45] and in a small, placebo-controlled study in adolescents with ASD [46].”
BackgroundThe brain serotonin system in autism
Rodnyy, A. Y., Kondaurova, E. M., Tsybko, A. S., Popova, N. K., Kudlay, D. A., & Naumenko, V. S. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0055 · Cited by 46
The promising trajectory of autism therapeutics discovery
Silverman, J. L., & Crawley, J. N. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.007 · Cited by 40
An Analysis of Treatment Efficacy for Stereotyped and Repetitive Behaviors in Autism
Mulligan, S., Healy, O., Lydon, S., Moran, L., & Foody, C. (2014) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-014-0015-8 · Cited by 43
Chantiluke, K., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2015) · Psychological Medicine · doi:10.1017/s0033291714002232 · Cited by 33
New perspectives in the treatment of body dysmorphic disorder
Hong, K., Nezgovorova, V., & Hollander, E. (2018) · F1000Research · doi:10.12688/f1000research.13700.1 · Cited by 31
Self-citationDecades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Henneberry, E. A., Lamy, M., Dominick, K. C., & Erickson, C. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05237-9 · Cited by 32
Järvinen, A. M., Laine, M. K., Tikkanen, R., & Castrén, M. L. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00097 · Cited by 35
Modulation of brain activation during executive functioning in autism with citalopram
Wichers, R., Findon, J. L., Jelsma, A., Giampietro, V., Stoencheva, V., Robertson, D., Murphy, C. M., McAlonan, G. M., Ecker, C., Rubia, K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0641-0 · Cited by 29
Bishop, J. R., Najjar, F., Rubin, L. H., Guter, S. J., Owley, T. B., Mosconi, M. W., Jacob, S., & Cook, E. H. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000173 · Cited by 32
Positron Emission Tomography in the Neuroimaging of Autism Spectrum Disorder: A Review
Tan, Z., Wei, H., Song, X., Mai, W., Yan, J., Ye, W., Ling, X., Hou, L., Zhang, S., Yan, S., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.806876 · Cited by 29
Brandenburg, C., & Blatt, G. J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14832 · Cited by 29
“Previously, Hollander et al. (2012) found improvement in repetitive behaviors in adult ASD subjects who were administered fluoxetine while McDougle et al. (1996), in a clinical trial using the SSRI fluvoxamine, reported improvement in aggressive behavior in adult ASD patients.”
ResultSeizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice
McMahon, J. J., Yu, W., Yang, J., Feng, H., Helm, M., McMahon, E., Zhu, X. C., Shin, D. S.-H., & Huang, Y. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.004 · Cited by 30
Preckel, K., Kanske, P., Singer, T., Paulus, F. M., & Krach, S. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1036-x · Cited by 25
Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes
Wang, H., Pati, S. B. B., Pozzo‐Miller, L. D., & Doering, L. C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00055 · Cited by 34
Holdman, R., Vigil, D., Robinson, K. J., Shah, P., & Contreras, A. E. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0154 · Cited by 39
Liang, S.-C., Sun, C., Fan, H.-Y., Chung, W., Tzang, R., Hung, K., Chiu, H., Cheng, Y., & Yeh, P. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210191 · Cited by 27
Neil, N. M., & Sturmey, P. (2013) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-013-0006-1 · Cited by 34
Personalized and precision medicine as informants for treatment management of bipolar disorder
Perugi, G., Rossi, P. D., Fagiolini, A. M., Girardi, P., Maina, G., Sani, G., & Serretti, A. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000260 · Cited by 33
Thom, R. P., Pereira, J. A., Sipsock, D., & McDougle, C. J. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01292-2 · Cited by 28
Martin, H., Choi, J. E., Rodrigues, A. R., & Eshel, N. (2024) · JAACAP Open · doi:10.1016/j.jaacop.2024.01.010 · Cited by 33
Scahill, L. D., & Challa, S. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-29695-1_3 · Cited by 24
What’s in the pipeline? Drugs in development for autism spectrum disorder
Sung, M., Chin, C. H., Lim, C. G., Liew, A., Lim, C. S., Kashala-Abotnes, E., & Weng, S. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39516 · Cited by 26
“44 Although older trials did not find fluvoxamine to be effective in younger patients with ASD, a randomized double-blind placebo-controlled crossover study reported that fluvoxamine was helpful in treating young patients, and found response to be related to polymorphism within a serotonin…”
Witt, N. A., Lee, B., Ghent, K., Zhang, W. Q., Pehrson, A., Sánchez, C., & Gould, G. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00386 · Cited by 19
Update on psychopharmacology for autism spectrum disorders
Bertelli, M. O., Rossi, M., Keller, R., & Lassi, S. (2016) · Advances in Mental Health and Intellectual Disabilities · doi:10.1108/amhid-10-2015-0049 · Cited by 20
Friedman, N. D. B., Politte, L. C., Nowinski, L. A., & McDougle, C. J. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch44 · Cited by 17
Wong, R. S.-Y. (2022) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-022-00525-2 · Cited by 20
Pharmacogenetic Study of Serotonin Transporter and 5HT2A Genotypes in Autism
Najjar, F., Owley, T. B., Mosconi, M. W., Jacob, S., Hur, K., Guter, S. J., Sweeney, J. A., Gibbons, R. D., Cook, E. H., & Bishop, J. R. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0158 · Cited by 19
Are there new advances in the pharmacotherapy of autism spectrum disorders?
Hollander, E., & Uzunova, G. (2017) · World Psychiatry · doi:10.1002/wps.20398 · Cited by 15
Self-citationVasudeva, S. B., & Hollander, E. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050559 · Cited by 18
Self-citationKowalewska, B., Dróżdż, W., & Kowalewski, Ł. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2021.15 · Cited by 17
Recent advancement in interventions for autism spectrum disorder: A review
Kalra, R., Gupta, M., & Sharma, P. (2023) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2023.100068 · Cited by 25
Kurahashi, H., Kunisawa, K., Tanaka, K. F., Kubota, H., Hasegawa, M., Miyachi, M., Moriya, Y., Hasegawa, Y., Nagai, T., Saito, K., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02004-z · Cited by 21
Coury, D. L., Swedo, S. E., Thurm, A. E., Miller, D. T., Veenstra-VanderWeele, J. M., Carbone, P. S., & Taylor, J. L. (2014) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2013.12.002 · Cited by 20
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options
Dell’Osso, L., Bonelli, C., Giovannoni, F., Poli, F., Anastasio, L., Cerofolini, G., Nardi, B., Cremone, I. M., Pini, S., & Carpita, B. (2025) · Pharmaceuticals · doi:10.3390/ph18030324 · Cited by 20
Taylor, L. J. (2016) · Research in Autism · doi:10.1016/j.rasd.2016.01.011 · Cited by 15
Lucchelli, J. P., & Bertschy, G. (2018) · Case Reports in Psychiatry · doi:10.1155/2018/6278501 · Cited by 18
Metadata
- Authors
- Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C.
- Affiliations
- Albert Einstein College of Medicine (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-03
- Volume
- 169
- Issue
- 3
- Pages
- 292-299
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2035017299
- Cited by
- 224
- References
- 25
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 18 · 2023: 15 · 2022: 20 · 2021: 13 · 2020: 13 · 2019: 17 · 2018: 18 · 2017: 14 · 2016: 12 · 2015: 21 · 2014: 25 · 2013: 16 · 2012: 6
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (U54MH066673, 1U54 MH-066673)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- fluoxetine, autism spectrum disorder, autistic adults, repetitive behavior, obsessive-compulsive symptoms, Yale-Brown Obsessive Compulsive Scale, Clinical Global Impression Scale, selective serotonin reuptake inhibitors, treatment response, drug tolerability
- MeSH terms
- Adolescent, Adult, Child, Child Development Disorders, Pervasive, Double-Blind Method, Female, Fluoxetine, Humans, Male, Middle Aged, Obsessive Behavior, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Stereotypic Movement Disorder, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.